Next Phase Newsletter

The life science venture investment arm of a leading global Private Equity firm with over $50 billion in AUM, is looking to make investments across development pipeline, from early to late stages. The firm’s investment size is highly variable depending on the stage of the company, ranging from $1M to $50M in equity. The firm has a global mandate and is actively seeking new investment opportunities.

The firm seeks compelling investment opportunities in drug discovery and development platforms developing novel therapeutics, personalized medicine, diagnostics, industrial biotechnology, healthcare services and IT. The firm does not invest in medical devices. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics.

The firm invests for the long term, and are heavily involved in, and committed to, the growth and success of their portfolio companies. The firm, therefore, generally take a board seat/observer rights. The firm only invests in private companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based backed by a world leading media and information company focuses on information technology and media companies based in the US, Europe, and Israel. The firm can allocate up to US$10M per company, preferably in the range of $3-5M. The firm will invest at any stage of a company’s development, from early/seed stage to growth capital. The firm is actively seeking new investment opportunities.

The firm currently seeks to invest across the Healthcare IT sector. The firm looks for any type of company that provides data and software to healthcare and life science companies including genomics and proteomics. Historically in the life sciences, the firm invested in a bioinformatics company that provides informatics to improve speed and productivity of drug delivery.

The firm may take a board or an observer seat depending on the amount of investment. For commercial stage companies, the firm looks for companies to have a revenue run rate of $1M plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm funded by a single LP based in the Western United States invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Series A and B financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

The firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. Generally, the firm focuses on opportunities that avoid or mitigate FDA regulatory risks. The firm is agnostic in terms of subsectors and indications, but does not consider orphan indications. The firm will only consider technologies with proof of concept. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm prefers to take a board seat but is generally flexible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A single family office based in the Western United States makes seed-stage and venture-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million. The firm is open to opportunities worldwide, and currently has portfolio companies in North America, Europe and Oceania.

The firm’s portfolio comprises ~30% of the total fund commitments, and is divided into two core categories. The first area of focus is Alzheimer’s Disease, where therapeutics (primary), diagnostics (secondary) and other solutions (tertiary) are all valid for consideration. The second area of investment is in technologies that enhance, accelerate, or reduce the cost of clinical trials and basic research, on the broadest scale, beyond Alzheimer’s Disease. This may include hardware and software tools, data analytics or aggregators, or novel approaches to current standards and protocols.

The firm seeks to make early-stage investments, but will also consider later-stage opportunities. The firm’s prior investments include drug discovery for the treatment of Alzheimer’s Disease, a diagnostic to track and recruit patients in early cognitive decline, a SaaS platform for clinical trial start-up workflow management, an automated imaging tool for micro-dissection of tissue samples, and a platform looking to reinvent the model for pre-human drug testing and development. The fund also has a global partnership to develop intellectual property into potential compound candidates to treat Alzheimer’s Disease.

The firm strongly prefers to invest in privately held companies and will only back top scientists with defendable research, pursuing breakthrough approaches; the fund does not invest in “me-too” ideas. In their Alzheimer’s portfolio, the fund looks to identify early-stage therapies that have received, and exhausted, non-dilutive sources of funding, such as grants from leading organizations; these companies will ideally be on the radar of large pharma counterparts but looking to obtain additional funds to collect the data required to form pharmaceutical partnerships. In the medical technology sector, the firm prefers to invest in companies developing platform technologies that can demonstrate and defend a clear value proposition addressing the ability to make clinical trials more efficient.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Taipei, Taiwan solely invests in early stage medical technology ventures. The firm currently manages a Medtech Fund which was raised in 2012 and closed at USD 100 million. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

The firm seeks a strong and experienced management team and typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Dublin, Ireland has approximately €100M AUM and focuses solely on the life sciences. The firm has 2 funds and plans to raise a third fund in the near future. The firm typically allocates between €5-7M of equity over the life of the investment. The firm primarily invests in companies that are based in Ireland and Europe. Exceptional opportunities in North America will also be considered. The firm is actively seeking new investment opportunities.

The firm invests in biotech therapeutic and diagnostic and medical device companies. For biotech, the firm prefers to invest in companies with first/best-in-class products in or nearing phase I, but will also consider phase II and outstanding companies in pre-clinical. For medical devices, the firm prefers companies with advanced prototype products or with initial clinical of concept completed. The firm is agnostic in terms of subsectors and indications, including orphan indications, but is very interested in products that address clear unmet opportunities. Historically, the firm invested in biotech therapeutics that addresses inflammatory, oncology, respiratory, autoimmune, and cardiovascular disorders. Medical devices: therapeutic for cardiovascular diseases, non-active implantable device for pulmonary embolism, renal and vascular diseases.

The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An evergreen life science venture fund located in Europe was established in 2009 and wholly owned by a strategic foundation. The fund’s evergreen structure allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. The fund has an annual investment capacity of approximately €50m. Investments are typically above €10-35m, and the firm prefers to take above 10% ownership. The fund is looking to invest primarily in Europe and in the USA/Canada.

The fund invests exclusively in life sciences, focusing on pharmaceuticals and medtech. For therapeutics, the firm typically prefers to invest at phase I/II but has also made investments at earlier phases of development. The fund will consider investing in medtech companies at the commercialization stage. The firm is open to opportunities in all therapeutic areas and indications.

The fund is oriented towards opportunities in the US and Europe and will take the role of lead investor in Europe. In US/Canada the firm prefers to syndicate with well-established VC investors specialized in life sciences. The fund expects to be actively in communication with management and represented on the supervisory board of portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com